What is HC Wainwright's Estimate for TRDA Q2 Earnings?

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Research analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Entrada Therapeutics in a report released on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($1.12) per share for the quarter. HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.42) EPS.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.36. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.

Entrada Therapeutics Price Performance

TRDA traded down $0.12 during midday trading on Wednesday, reaching $7.50. 103,059 shares of the company's stock were exchanged, compared to its average volume of 130,598. Entrada Therapeutics has a 1-year low of $7.10 and a 1-year high of $21.79. The stock has a market capitalization of $284.65 million, a PE ratio of 4.72 and a beta of 0.04. The business's 50-day moving average price is $8.64 and its 200 day moving average price is $13.11.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Merck & Co. Inc. purchased a new stake in shares of Entrada Therapeutics in the first quarter valued at $15,728,000. Janus Henderson Group PLC raised its stake in Entrada Therapeutics by 21.6% in the 4th quarter. Janus Henderson Group PLC now owns 2,080,367 shares of the company's stock valued at $36,011,000 after purchasing an additional 368,908 shares during the last quarter. Vanguard Group Inc. raised its stake in Entrada Therapeutics by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock valued at $25,317,000 after purchasing an additional 241,052 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Entrada Therapeutics by 123.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 222,520 shares of the company's stock valued at $3,847,000 after purchasing an additional 122,823 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Entrada Therapeutics by 127.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 217,006 shares of the company's stock worth $3,752,000 after purchasing an additional 121,598 shares during the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.